Media Fill Failures: What FDA's 2026 Warning Letters Reveal About Aseptic Process Simulation

Sterile drug manufacturing has no room for a second chance. When a vial of injectable, an ophthalmic solution, or a filled cartridge cannot be terminally sterilized, the process itself has to guarantee sterility, and the only way to prove that the process works is to run it with growth medium instead of product and see whether anything grows. That test is the media fill, also called an aseptic process simulation. In 2026 it has become one of the most cited failure points in United States Food and Drug Administration (FDA) enforcement.

A run of FDA warning letters issued through 2026 describes sterile and over the counter drug makers whose aseptic lines were, in the agency's words, inadequately designed, controlled, and monitored to prevent contamination, and in several cases firms that continued to release product after a media fill had failed. For any company that fills a sterile product, the message is direct: a media fill programme that looks complete on paper but is weak in design or discipline is now a leading route to a Form 483 observation, a warning letter, and a recall. This article explains what aseptic process simulation is, the rules that govern it in Canada, the United States, and the European Union, and how to build a programme that holds up when an inspector arrives.

Executive summary

A media fill substitutes sterile microbiological growth medium for product and runs the full aseptic filling process to confirm that the process can produce sterile units. Health Canada, the FDA, and European Union good manufacturing practice (GMP) all expect initial qualification with three consecutive successful runs across every shift, repeat simulations roughly twice a year for each line and shift, incubation of the filled units, and clear acceptance criteria tied to run size. A single contaminated unit is never routine: it triggers a formal investigation, and depending on run size and findings it can require full revalidation. Releasing product made on a line after a failed media fill, without a completed and justified investigation, is a serious quality and data integrity failure that FDA is actively citing in 2026.

What is a media fill, and why does it matter?

A media fill is a simulation of the aseptic filling process in which sterile growth medium replaces the drug product, so that any contamination introduced by the line, the environment, or the operators shows up as microbial growth. It is the practical proof behind sterility assurance for products that cannot be terminally sterilized. If the simulated process stays sterile, the aseptic process is considered capable of producing sterile product under the conditions tested.

Why it matters is simple. Sterility testing at the end of the line samples only a small number of units and cannot detect a low, sporadic contamination rate. The media fill, by contrast, challenges the whole process: setup, interventions, operator technique, environmental control, and time. It is the closest a manufacturer can get to asking, honestly, whether the line makes sterile product. Regulators treat it as a core validation activity under 21 CFR 211.113 in the United States, Annex 1 of the European Union GMP guide, and the aseptic processing expectations Health Canada applies through its GMP guidelines and inspections.

For Canadian manufacturers and importers, the same expectations arrive through more than one door. A drug establishment licence holder filling sterile product in Canada is inspected against Health Canada GMP. A company exporting to the United States is judged against FDA current good manufacturing practice. A site seeking European Union market access is measured against Annex 1. The technical core, a well designed and disciplined aseptic process simulation, is common to all three.

What FDA's 2026 sterile-drug warning letters reveal

Through 2026, FDA has issued a cluster of warning letters to sterile and over the counter drug manufacturers citing aseptic processing that was inadequately designed, controlled, and monitored, repeated media fill failures, and batch failure investigations that were never properly completed. Read together, they map the exact places a media fill programme breaks down and becomes an enforcement finding.

One example is K.C. Pharmaceuticals, a Pomona, California maker of sterile over the counter eye drops, which received an FDA warning letter dated 12 August 2026. The letter followed repeat sterility problems dating back to 2024 and an earlier warning letter in 2023, and it accompanied a recall of multiple over the counter eye drop lines for lack of assurance of sterility tied to the aseptic filling process used between 27 March and 7 November 2024. The pattern FDA describes, a firm already on notice for sterility failures that did not fix the underlying aseptic process, is precisely the situation a robust media fill programme is meant to prevent.

The same year, American Regent recalled three lots of epinephrine injection for particulate matter and a lack of assurance of sterility, a reminder that container closure and sterility findings often travel together. Across the 2026 letters, three themes recur: aseptic lines that were not designed to a worst case, media fills that failed and were not fully investigated, and product that was released anyway. FDA is reading these not as isolated microbiology events but as failures of quality oversight and batch disposition.

How often, and how many units: the rules that govern aseptic process simulation

Initial qualification of an aseptic line requires three consecutive successful media fills covering every shift and every operator involved, after which each line and shift is normally re-simulated about twice a year, roughly every six months. Individual operators are requalified on a defined schedule, and any significant change to the line, the process, or the facility triggers a repeat simulation.

Run size matters because it sets the statistical sensitivity of the test. FDA's 2004 guidance on sterile drug products produced by aseptic processing recommends media fill runs generally in the range of 5,000 to 10,000 units, and where a routine batch is smaller than 5,000 units the media fill should at least match the batch size. The goal is a process capable of a contamination rate below 0.1 percent with a 95 percent confidence level.

Each filled unit is then incubated, normally for at least 14 days, at conditions that support both bacterial and fungal growth, commonly a period at 20 to 25 degrees Celsius and a period at 30 to 35 degrees Celsius, followed by a read by qualified personnel. Growth promotion testing confirms the medium can actually support recovery of a panel of organisms, because a media fill that would not grow contamination proves nothing. These expectations are consistent across the FDA guidance, European Union GMP Annex 1, and the PIC/S recommendation on the validation of aseptic processes.

Media fill acceptance criteria

The acceptance criteria in FDA's 2004 guidance and in European Union GMP Annex 1 are aligned and are built around run size. The table below summarizes them. In every case the target for a run under 5,000 units is zero contaminated units, and any contamination at all requires a documented investigation before the line returns to routine use.

These thresholds are not a licence to accept one contaminated unit as normal. They describe the regulatory response to a positive result, not an acceptable rate of contamination. A recurring single positive across successive media fills is itself a signal that the aseptic process is not in control.

Can you release product after a failed media fill?

No. Product made on a line associated with a failed media fill must not be released until a thorough, documented investigation determines the root cause and establishes, with justification, that released or in process batches are not affected. Doing otherwise is the single finding FDA has cited most sharply in the 2026 sterile drug letters.

A failed media fill is a batch failure in regulatory terms, and it pulls in the batch failure investigation requirement at 21 CFR 211.192 in the United States and the equivalent deviation and investigation expectations under Health Canada and European Union GMP. The investigation must consider every batch that could be implicated, extend to other lines or products where the root cause could reach, and drive corrective and preventive action (CAPA). Where the affected fill was performed by a contract manufacturer, the sponsor's oversight of that contractor is part of the finding. Quality assurance, not production, owns the disposition decision. If the investigation cannot rule out an impact on distributed product, the honest and compliant path may be a recall, classified by the relevant authority under its recall rules.

Designing a media fill that survives inspection

A defensible media fill reproduces the worst case of routine production, not an idealized version of it. Inspectors look for a simulation that is at least as stressful as the real process, that includes the interventions operators actually perform, and that is supported by sound environmental and personnel controls.

Each of these elements should be anchored in a documented protocol and a broader validation master plan. The following design elements separate a media fill that reassures an inspector from one that invites questions:

• Worst case duration and line speed. Simulate the longest permitted campaign or holding time and the line speed that presents the greatest contamination risk, with a documented rationale for each.
• Realistic interventions. Include every routine and non routine intervention operators perform, such as stopper hopper refills, weight checks, and line stoppage recoveries, and record them so the simulation reflects real behaviour.
• Full shift and operator coverage. Cover every shift, shift change, and operator involved in aseptic operations, because contamination often enters through people and handovers.
• Adequate run size. Match run size to the guidance ranges, and where routine batches are small, at least match the batch size so the test has statistical meaning.
• Container closure representativeness. Use the same container closure system and, where relevant, verify its integrity separately, because a sterile fill in a leaking container is not sterile on the shelf.
• Integrated environmental monitoring. Run viable and non viable monitoring during the fill so a positive media unit can be interpreted against the environment of that run.
• Growth promotion and incubation control. Confirm the medium supports growth, incubate for the full period at the specified temperatures, and have qualified readers interpret the units.
• A pre agreed response plan. Define, before a run fails, how the line is quarantined, how affected batches are identified, and who authorizes any release.

Media fill and aseptic process simulation: compliance checklist

Use this checklist to test your own aseptic process simulation programme against current expectations. It is a starting point, not a substitute for a formal gap assessment against Health Canada, FDA, and Annex 1 requirements.

• Initial qualification used three consecutive successful media fills covering every shift.
• Each line and shift is re-simulated at least twice a year, roughly every six months.
• Every operator who performs aseptic operations is qualified and requalified on a defined schedule.
• Run size matches guidance, and small routine batches are matched unit for unit.
• The simulation includes worst case duration, line speed, and all routine and non routine interventions.
• Filled units are incubated for the full period at temperatures supporting bacterial and fungal growth, then read by qualified staff.
• Growth promotion testing is performed on the medium used.
• Environmental and personnel monitoring runs concurrently and is reviewed against media fill results.
• Acceptance criteria are documented and tied to run size, and any positive triggers a formal investigation.
• A written procedure prohibits release of affected product until an investigation is complete and justified, and media fill failures feed a CAPA system with trend review across runs.

Common mistakes that turn a media fill into a warning letter

The findings in the 2026 letters, and in Health Canada and European inspection reports, tend to repeat. The most common failures are avoidable:

• Simulating a best case. Short runs, minimal interventions, and ideal conditions produce a media fill that passes but proves nothing about routine production.
• Under scoping interventions. Leaving out the awkward, real world interventions operators actually perform is one of the most frequent gaps inspectors find.
• Treating one positive as noise. Accepting a single contaminated unit without a rigorous investigation ignores what the result is telling you.
• Releasing before investigating. Disposition of product from an affected line before the investigation closes is the finding FDA has cited most severely in 2026.
• Weak growth promotion. Failing to confirm the medium can recover organisms undermines every negative result the programme produces.
• Ignoring the container closure. A sterile fill into a container that later fails integrity testing is not sterile in the field, as recent particulate and sterility recalls show.
• Not trending. Reviewing media fills only one run at a time misses the slow drift that precedes a failure.
• Stale requalification. Letting operator or line requalification lapse leaves the most contamination prone parts of the process unverified.

Frequently asked questions

What is the difference between a media fill and an aseptic process simulation?

There is none in practice. Aseptic process simulation is the formal regulatory term, and media fill is the common name for the same test, because the process is run with sterile growth medium in place of product. Guidance documents use the terms interchangeably.

How many media fills are required each year?

After initial qualification with three consecutive successful runs, each aseptic line and shift is normally re-simulated about twice a year, roughly every six months. Individual operators are requalified on a defined schedule, and any significant change to the line, process, or facility triggers an additional simulation.

How many units should a media fill contain?

FDA guidance recommends runs generally between 5,000 and 10,000 units. Where a routine batch is smaller than 5,000 units, the media fill should at least match the batch size, so the test retains enough statistical sensitivity to detect a low contamination rate.

What happens if a media fill fails?

A failed media fill is treated as a batch failure. The line and affected product are quarantined, a formal investigation determines the root cause and the scope of impact, corrective and preventive actions follow, and depending on run size and findings the process may need revalidation. Product is not released until the investigation justifies it.

Can product be released after a failed media fill?

Not until a documented investigation establishes that the released or in process batches are not affected. Releasing product from a line associated with a failed media fill, before the investigation is complete and justified, is a serious quality and data integrity failure and a recurring finding in FDA's 2026 warning letters.

Do the media fill rules differ between FDA and EU GMP Annex 1?

The core expectations are closely aligned. Both require three consecutive successful runs for initial qualification, periodic re-simulation, incubation and growth promotion, and the same run size based acceptance criteria. Annex 1 places added emphasis on the contamination control strategy that surrounds the process, so a manufacturer serving both markets should design to the stricter combined expectation.

How MFLRC can help

MF License and Regulatory Consultants (MFLRC) is a Canadian regulatory and quality consultancy that helps sterile and other manufacturers build aseptic processing programmes that hold up under Health Canada, FDA, and European Union inspection. Our validation and quality specialists have supported facilities across pharmaceuticals, natural health products, medical devices, and cannabis, and we translate the 2026 enforcement pattern into practical, defensible controls.

We can pressure test your aseptic process simulation before a regulator does. That includes pharmaceutical validation services covering media fill protocol design, environmental monitoring, and container closure integrity method selection, GMP audit and mock inspection to expose gaps ahead of a pre approval or routine inspection, CAPA and batch failure investigation support so a deviation is handled defensibly, and quality assurance batch disposition governance so release decisions are documented and sound. If you are building or repairing a programme, a focused GMP inspection readiness gap assessment against Annex 1 and FDA expectations is usually the fastest first step.

Facing a media fill deviation, or preparing a sterile facility for inspection? MFLRC can help you get ahead of it.

Conclusion

The media fill is the honest test of an aseptic process, and in 2026 it has become one of the clearest dividing lines between manufacturers that control contamination and those that do not. The regulatory rules are stable and well documented: three qualifying runs, periodic re-simulation, run size based acceptance criteria, full incubation and growth promotion, and an absolute prohibition on releasing product from a line after a failed simulation until an investigation justifies it. The firms named in this year's warning letters did not fail because the rules were unclear. They failed on design, discipline, and disposition. A media fill programme built to the worst case, investigated rigorously, and governed by quality assurance is not only compliant, it is the most reliable protection a sterile manufacturer has for its patients and its licence.

Sources and references

• FDA, Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing, Current Good Manufacturing Practice (2004)
• European Commission, EudraLex Volume 4, Annex 1: Manufacture of Sterile Medicinal Products (2022)
• US Code of Federal Regulations, 21 CFR 211.113, Control of microbiological contamination
• US Code of Federal Regulations, 21 CFR 211.192, Production record review
• FDA, Warning Letter to K.C. Pharmaceuticals, Inc. (12 August 2026)
• FDA, American Regent Voluntary Nationwide Recall of Epinephrine Injection, USP (2026)
• FDA, Warning Letters database